Royal Philips

Philips again recognized as a Clarivate Top 100 Global Innovator

Philips again recognized as a Clarivate Top 100 Global Innovator

February 26, 2021

For the eighth consecutive year, Philips wins a Top-100 place for the volume, influence, success and globalization of its innovation

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has once again been recognized as a Clarivate Top 100 Global Innovator™ in Clarivate Analytics’ 2021 list, which identifies the world’s most innovative companies by measuring the ideation culture that produces patents [1]. Philips has now successively won a place on this prestigious list for eight consecutive years.

“Our global R&D program and strong intellectual property portfolio continue to fuel our ability to truly impact global health challenges through innovation,” said Frans van Houten, CEO of Royal Philips. “I am very pleased that we have again been named as a Clarivate Top 100 Global Innovator, for the 8th consecutive year. This is another much-valued recognition of our ability to create breakthrough innovations that improve people's health and well-being.”

Philips’ EUR 1.9 billion R&D program has resulted in the introduction of many successful recent innovations, including:

The ‘Clarivate Top 100 Global Innovators 2021’ come from three continents and 14 countries/regions. The report and a full list of the Top 100 organizations can be found here.

 [1] To compile its ‘Clarivate Top 100 Global Innovators’ list, Clarivate tracks innovation based on four indicators: 1. Volume: A volume threshold of 100 granted inventions in the past five years and more than 500 filed in total over any time period. 2. Influence: Patented ideas' level of influence based on the number of external citations an organization's inventions has received in the past five years -- references made to an organization's patents during the application and examination process from patents later registered by someone else. 3. Success: The level of success in getting patent protection applications issued by the patent offices of the world in the same five-year window. 4. Globalization: The level of investment in an organization's patent applications, to determine the footprint of commercialization and patent application investment, measured by filing activity level in Europe, Japan, Mainland China and the United States, jurisdictions that speak to significant cost.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: [email protected]

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: [email protected]

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at